Molecular Bacteriology Research Associate: Polymyxin Mechanisms

Imperial Enterprise; Greater London; Sur place; GBP 51 000 - 59 000; Plein temps

Avantages offerts par ce poste

Sector-leading salary package

On-site work

World-leading institution

Diverse, inclusive culture

Résumé du poste

Imperial College London is seeking a Research Associate in Molecular Bacteriology to join the Edwards group within the Department of Infectious Disease. The post will explore how polymyxin antibiotics kill Gram-negative bacteria and will include experimental planning, data analysis, and manuscript preparation.

The appointment is full-time, fixed-term for 12 months, starting October 2026 or as soon as possible thereafter, with research focusing on antimicrobial resistance and membrane biology in

Qualifications

• PhD in bacteriology or related field.
• Experience in genetic manipulation of Gram-negative bacteria.
• Experience in nanoscale imaging techniques including AFM.
• Ability to work collaboratively, experience in experimental planning, troubleshooting, data analysis, and safe laboratory working practices.

Responsabilités

• Lead studies to understand how polymyxins function in Gram-negative bacteria.
• Plan experiments, analyze data, and present findings; contribute to manuscript writing.
• Work in a dynamic, collaborative environment within the Edwards group and the Centre for Bacterial Resistance Biology.
• Ensure safe laboratory practices and adherence to project timelines.

Connaissances

Genetic manipulation

AFM imaging

Experiment planning

Data analysis

Lab safety

Collaboration

Formation

PhD in bacteriology or related field

Description du poste

Imperial College London is seeking a Research Associate in Molecular Bacteriology to join the Edwards group within the Department of Infectious Disease. The post will explore how polymyxin antibiotics kill Gram-negative bacteria and will include experimental planning, data analysis, and manuscript preparation.

The appointment is full-time, fixed-term for 12 months, starting October 2026 or as soon as possible thereafter, with research focusing on antimicrobial resistance and membrane biology in